Home › Funds › SANDS CAPITAL MANAGEMENT, LLC › RARE

SANDS CAPITAL MANAGEMENT, LLC position in RARE

ULTRAGENYX PHARMACEUTICAL IN · Health Care

SANDS CAPITAL MANAGEMENT, LLC reported holding 3,158,368 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$105.5M, representing 0.39% of its reported portfolio and ranking #47 among its reported holdings. SANDS CAPITAL MANAGEMENT, LLC has disclosed RARE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.16M sh
Reported value held$105.46M
Portfolio Weight0.39%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SANDS CAPITAL MANAGEMENT, LLC's RARE position evolved

SANDS CAPITAL MANAGEMENT, LLC first disclosed a stake in RARE in Q3 2023 at 2,577,217 shares (US$91.9M). The position peaked in Q3 2024 at 5,118,255 shares, worth US$284.3M. Across 12 filings, SANDS CAPITAL MANAGEMENT, LLC increased the stake 2 time(s), trimmed it 9 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,158,368 shares valued at US$105.5M — a reduction of -56,165 shares quarter over quarter.. Notable position changes include a 60% increase in Q4 2023 (shares fell 2% over the following quarter), a 39% increase in Q2 2024 (shares rose 35% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.58M $91.88M New
Q4 2023 4.12M $196.92M Add
Q1 2024 3.86M $180.20M Reduce
Q2 2024 5.35M $220.08M Add
Q3 2024 5.12M $284.32M Reduce
Q4 2024 4.30M $180.82M Reduce
Q1 2025 4.16M $150.76M Reduce
Q2 2025 3.94M $143.39M Reduce
Q3 2025 3.77M $113.40M Reduce
Q4 2025 3.49M $80.17M Reduce
Q1 2026 3.21M $67.34M Reduce
Q2 2026 3.16M $105.46M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RARE and 13F data

RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 26 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M), Bellevue Group AG (US$66.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RARE

All RARE fund holders →

FAQ

How long has SANDS CAPITAL MANAGEMENT, LLC held RARE?

SANDS CAPITAL MANAGEMENT, LLC has disclosed RARE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is SANDS CAPITAL MANAGEMENT, LLC's current position in RARE?

As of Q2 2026, SANDS CAPITAL MANAGEMENT, LLC holds 3.16M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $105.46M, representing 0.39% of its reported portfolio and ranking #47.

Has SANDS CAPITAL MANAGEMENT, LLC been buying or selling RARE?

In the latest 13F filing (Q2 2026), SANDS CAPITAL MANAGEMENT, LLC reduced its position in RARE. The position peaked in Q3 2024 at 5.12M shares.

Which other funds hold RARE?

Other major institutional holders of RARE include RTW INVESTMENTS, LP, FRONTIER CAPITAL MANAGEMENT CO LLC, Bellevue Group AG, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.